|Genetic Modifiers - Meetings - Meeting September 2005
The proposed Euro-HD genetic modifiers working
group will meet in Manchester
for the first time to discuss possible clinical phenotypes that might be
susceptible to genetic analysis given the large collection of HD patients and
data on natural history of the disease being collected as part of Euro-HD. We aim to discuss the possibility of using
the Euro-HD network to analyse genetic influences on the phenotype of the
disease. We would like to invite
participants in Euro-HD to attend the working group with a view to establishing
a programme that will allow current and future research examining specific
traits that participants in the network are interested in.
We hope any member of Euro-HD interested in such
research will be able to attend.
We wish to investigate the way in which such analyses should be structured
and eventually carried out, thus at our initial meeting we will discuss the
Identification traits of interest (broad group).
Examination of the
relevant clinical scales to make sure they will give quantitative scores that will
be useful in genetic analysis (geneticists, clinicians, statistical
heritability of those traits (biostatistician)
sample size to give appropriate power to identify genetic markers of specific
effect sizes by linkage or association (biostatistician).
What is the best
way to move these things forward? For
instance, are there specific people we should invite to participate in the
group? Should we employ a biostatistician?
Where will the funding come from?
| || |